Gast ::
| Hauptseite > Publikationsdatenbank > Beneficial effects of bilateral subthalamic stimulation on alexithymia in Parkinson's disease > print |
| Hauptseite > Publikationsdatenbank > Beneficial effects of bilateral subthalamic stimulation on alexithymia in Parkinson's disease > print |
| 001 | 851195 | ||
| 005 | 20210129234805.0 | ||
| 024 | 7 | _ | |a 10.1111/ene.13773 |2 doi |
| 024 | 7 | _ | |a 1351-5101 |2 ISSN |
| 024 | 7 | _ | |a 1468-1331 |2 ISSN |
| 024 | 7 | _ | |a 1471-0552 |2 ISSN |
| 024 | 7 | _ | |a pmid:30107062 |2 pmid |
| 024 | 7 | _ | |a WOS:000455803800006 |2 WOS |
| 037 | _ | _ | |a FZJ-2018-04895 |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |0 P:(DE-HGF)0 |a Dafsari, Haidar S. |b 0 |e Corresponding author |
| 245 | _ | _ | |a Beneficial effects of bilateral subthalamic stimulation on alexithymia in Parkinson's disease |
| 260 | _ | _ | |a Oxford |b Blackwell Science91133 |c 2019 |
| 264 | _ | 1 | |2 Crossref |3 online |b Wiley |c 2018-09-21 |
| 264 | _ | 1 | |2 Crossref |3 print |b Wiley |c 2019-02-01 |
| 264 | _ | 1 | |2 Crossref |3 print |b Wiley |c 2019-02-01 |
| 336 | 7 | _ | |2 DRIVER |a article |
| 336 | 7 | _ | |2 DataCite |a Output Types/Journal article |
| 336 | 7 | _ | |0 PUB:(DE-HGF)16 |2 PUB:(DE-HGF) |a Journal Article |b journal |m journal |s 1547820055_32150 |
| 336 | 7 | _ | |2 BibTeX |a ARTICLE |
| 336 | 7 | _ | |2 ORCID |a JOURNAL_ARTICLE |
| 336 | 7 | _ | |0 0 |2 EndNote |a Journal Article |
| 520 | _ | _ | |a Background and purposeSubthalamic nucleus (STN) deep brain stimulation (DBS) improves quality of life (QoL) and motor and non‐motor symptoms in advanced Parkinson's disease (PD). However, its effect on alexithymia and its relationship to other neuropsychiatric symptoms and QoL in PD is unclear.MethodsIn this prospective, observational study of 39 patients with PD undergoing STN‐DBS, we examined the Parkinson's Disease Questionnaire‐8 (PDQ‐8), 20‐item Toronto Alexithymia Scale (TAS‐20), Hospital Anxiety and Depression Scale (HADS), Self‐Report Manic Inventory (SRMI), Apathy Evaluation Scale (AES), Unified Parkinson's Disease Rating Scale (UPDRS) activities of daily living, UPDRS motor examination and UPDRS complications (UPDRS‐II/‐III/‐IV) and levodopa‐equivalent daily dose (LEDD) pre‐operatively and at 5‐month follow‐up. Outcome changes were tested with Wilcoxon signed‐rank or paired t‐test when parametric tests were applicable and corrected for multiple comparisons. The relationship between outcome changes was explored with bivariate correlations. Additionally, partial correlations between PDQ‐8 and TAS‐20 were computed controlling for HADS, SRMI and AES change scores. Predictor analyses for PDQ‐8 improvement were calculated for all baseline parameters.ResultsThe baseline prevalence of alexithymia was 17.9%. We observed significant beneficial effects of STN‐DBS on PDQ‐8, TAS‐20, HADS, UPDRS‐II, ‐III and ‐IV scores and significant LEDD reduction. The correlation between TAS‐20 and PDQ‐8 improvements remained significant after controlling for all other aforementioned outcomes. Predictor analyses for PDQ‐8 improvement were significant for PDQ‐8 and TAS‐20.ConclusionsThis is the first report of beneficial effects of STN‐DBS on alexithymia. Alexithymia was significantly associated with QoL outcome independent of anxiety, depression, mania and apathy. Our study highlights the importance of alexithymia for holistic assessments of DBS outcomes. |
| 536 | _ | _ | |0 G:(DE-HGF)POF3-572 |a 572 - (Dys-)function and Plasticity (POF3-572) |c POF3-572 |f POF III |x 0 |
| 542 | _ | _ | |2 Crossref |i 2018-09-21 |u http://doi.wiley.com/10.1002/tdm_license_1.1 |
| 542 | _ | _ | |2 Crossref |i 2018-09-21 |u http://onlinelibrary.wiley.com/termsAndConditions#vor |
| 588 | _ | _ | |a Dataset connected to CrossRef |
| 700 | 1 | _ | |0 P:(DE-HGF)0 |a Chaudhuri, K. Ray |b 1 |
| 700 | 1 | _ | |0 P:(DE-HGF)0 |a Mahlstedt, Picabo |b 2 |
| 700 | 1 | _ | |0 P:(DE-HGF)0 |a Sachse, Lena |b 3 |
| 700 | 1 | _ | |0 P:(DE-HGF)0 |a Steffen, Julia K. |b 4 |
| 700 | 1 | _ | |0 P:(DE-HGF)0 |a Petry-Schmelzer, Jan Niklas |b 5 |
| 700 | 1 | _ | |0 P:(DE-HGF)0 |a Dembek, Till A. |b 6 |
| 700 | 1 | _ | |0 P:(DE-HGF)0 |a Reker, Paul |b 7 |
| 700 | 1 | _ | |0 P:(DE-Juel1)131613 |a Barbe, Michael |b 8 |
| 700 | 1 | _ | |0 P:(DE-HGF)0 |a Visser-Vandewalle, Veerle |b 9 |
| 700 | 1 | _ | |0 P:(DE-Juel1)131720 |a Fink, Gereon R. |b 10 |
| 700 | 1 | _ | |0 P:(DE-HGF)0 |a Timmermann, Lars |b 11 |
| 773 | 1 | 8 | |2 Crossref |3 journal-article |a 10.1111/ene.13773 |b : Wiley, 2018-09-21 |n 2 |p 222-e17 |t European Journal of Neurology |v 26 |x 1351-5101 |y 2019 |
| 773 | _ | _ | |0 PERI:(DE-600)2020241-6 |a 10.1111/ene.13773 |n 2 |p 222-e17 |t European journal of neurology |v 26 |x 1351-5101 |y 2019 |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/851195/files/Dafsari_et_al-2019-European_Journal_of_Neurology.pdf |y Restricted |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/851195/files/Dafsari_et_al-2019-European_Journal_of_Neurology.pdf?subformat=pdfa |x pdfa |y Restricted |
| 909 | C | O | |o oai:juser.fz-juelich.de:851195 |p VDB |
| 910 | 1 | _ | |0 I:(DE-588b)5008462-8 |6 P:(DE-Juel1)131613 |a Forschungszentrum Jülich |b 8 |k FZJ |
| 910 | 1 | _ | |0 I:(DE-588b)5008462-8 |6 P:(DE-Juel1)131720 |a Forschungszentrum Jülich |b 10 |k FZJ |
| 913 | 1 | _ | |0 G:(DE-HGF)POF3-572 |1 G:(DE-HGF)POF3-570 |2 G:(DE-HGF)POF3-500 |a DE-HGF |b Key Technologies |l Decoding the Human Brain |v (Dys-)function and Plasticity |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |
| 914 | 1 | _ | |y 2019 |
| 915 | _ | _ | |0 StatID:(DE-HGF)0200 |2 StatID |a DBCoverage |b SCOPUS |
| 915 | _ | _ | |0 StatID:(DE-HGF)0300 |2 StatID |a DBCoverage |b Medline |
| 915 | _ | _ | |0 StatID:(DE-HGF)0310 |2 StatID |a DBCoverage |b NCBI Molecular Biology Database |
| 915 | _ | _ | |0 StatID:(DE-HGF)0100 |2 StatID |a JCR |b EUR J NEUROL : 2015 |
| 915 | _ | _ | |0 StatID:(DE-HGF)0600 |2 StatID |a DBCoverage |b Ebsco Academic Search |
| 915 | _ | _ | |0 StatID:(DE-HGF)0030 |2 StatID |a Peer Review |b ASC |
| 915 | _ | _ | |0 StatID:(DE-HGF)0199 |2 StatID |a DBCoverage |b Thomson Reuters Master Journal List |
| 915 | _ | _ | |0 StatID:(DE-HGF)0111 |2 StatID |a WoS |b Science Citation Index Expanded |
| 915 | _ | _ | |0 StatID:(DE-HGF)0150 |2 StatID |a DBCoverage |b Web of Science Core Collection |
| 915 | _ | _ | |0 StatID:(DE-HGF)1110 |2 StatID |a DBCoverage |b Current Contents - Clinical Medicine |
| 915 | _ | _ | |0 StatID:(DE-HGF)1050 |2 StatID |a DBCoverage |b BIOSIS Previews |
| 915 | _ | _ | |0 StatID:(DE-HGF)9900 |2 StatID |a IF < 5 |
| 920 | _ | _ | |l yes |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-3-20090406 |k INM-3 |l Kognitive Neurowissenschaften |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-Juel1)INM-3-20090406 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|